Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies.
Open Access
- 1 July 2001
- journal article
- review article
- Published by SAGE Publications in Cancer Control
- Vol. 8 (4) , 326-336
- https://doi.org/10.1177/107327480100800404
Abstract
Lung cancer continues to be the leading cause of cancer-related deaths for Americans. As most patients present with nonsurgically curable disease, major efforts have been made in the treatment of advanced non-small-cell lung cancer (NSCLC) with chemotherapy. Several new agents and new combinations of chemotherapy are available.Keywords
This publication has 34 references indexed in Scilit:
- Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issuesExpert Opinion on Investigational Drugs, 2000
- Gene therapy for lung cancerCurrent Opinion in Oncology, 2000
- Second–line chemotherapy for non—small–cell lung cancerCurrent Oncology Reports, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1999
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non small cell lung cancer (NSCLC)Lung Cancer, 1994
- C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.Journal of Clinical Investigation, 1994
- Inhibition of Human Lung Cancer Cell Line Growth by an Anti-p185HER2 AntibodyAmerican Journal of Respiratory Cell and Molecular Biology, 1993
- Chemotherapy of Lung CancerNew England Journal of Medicine, 1992